2023-09-28 07:27:25 ET
(24/7 MARKET NEWS) – Bionomics Limited (NASDAQ: BNOX) reported, this morning, that its Phase 2b ATTUNE trial of BNC210 for the treatment of PTSD achieved positive topline results. The ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks and was well-tolerated with a safety profile supporting chronic administration.
Bionomics Limited is trading at $1.92, up $0.935 (+94.92%%), on 3.7M premarket shares traded.
Its 52-week range is $0.93 to 10.90. Its next key inflection point is $2 and the only thing between that and $2.50 are a couple of price spike days.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various …
The post Bionomics Moving on Phase 2b ATTUNE Clinical Trial Positive Topline Results appeared first on 24/7 Market News .
For further details see:
Bionomics Moving on Phase 2b ATTUNE Clinical Trial Positive Topline Results